The effect of ginger on glycemic status, apolipoprotein B, apolipoprotein A-I, total antioxidant capacity (TAC), malondialdehyde (MDA), high sensitivity c-reactive protein (hsCRP), and paraoxonase in type 2 diabetic patiants

The effect of ginger on glycemic status, apolipoprotein B, apolipoprotein A-I, total antioxidant capacity (TAC), malondialdehyde (MDA), high sensitivity c-reactive protein (hsCRP), and paraoxonase in type 2 diabetic patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201109082709N19

Enrollment

Registered

2011-10-07

Start date

2011-10-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetese melitus. R81

Interventions

Intervention 1: intervention group : ginger supplement, 3 gram per day and during 3 months. Intervention 2: control group : lactose supplement, 2 grams per day and during 3 months.

Treatment - Drugs

intervention group : ginger supplement, 3 gram per day and during 3 months

control group : lactose supplement, 2 grams per day and during 3 months

Eligibility

Sex/Gender

All

Age

20 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria:Non-insulin dependent diabetic patients with type 2 diabetes that is diagnosed by a physician, Endocrinologist.Diabetes duration of at least 2 years , 20-60 ages,Hb A1c :6-8% , Lack of antioxidant supplements such as selenium, zinc, beta carotene, and ... At least 3 months before the study - not smoking, and alcohol - a willingness to cooperate with exclusion criteria: Patient unwillingness to continue with the plan - changes in type or dose of medication, Changes in diet or physical activity every day - taking any antioxidant supplements - taking less than 80% of supplements given to patients at baseline(the compaliance lower than %80),Recent receive insulin - pregnancy and lactation - renal , hepatic , thyroid diseases and anemia - hypersensitivity to the drug

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Fasting blood sugar. Timepoint: before & after intervention (3 months later). Method of measurement: glucose oxidase method.;Hb A1C. Timepoint: before & after intervention (3 months later). Method of measurement: colorimetry.;Insulin. Timepoint: before & after intervention (3 months later). Method of measurement: IRMA.;Insulin resistance. Timepoint: before & after intervention (3 months later). Method of measurement: insulin × glucose / 22.5.;Apo A. Timepoint: before & after intervention (3 months later). Method of measurement: immunotorbidometry.;Apo B. Timepoint: before & after intervention (3 months later). Method of measurement: immunotorbidometry.;Apo B/Apo A-I. Timepoint: before & after intervention (3 months later). Method of measurement: ratio.;High-sensitivity C-Reactive Protein. Timepoint: before & after intervention (3 months later). Method of measurement: ELISA kitt.;Total antioxidant capacity. Timepoint: before & after intervention (3 months later). Method of measurement: colorimetry (FRAP).;Malondealdehyde. Timepoint: before & after intervention (3 months later). Method of measurement: colorimetry.;Paraoxonase. Timepoint: before & after intervention (3 months later). Method of measurement: colorimetry.	—

Measure

Time frame

Fasting blood sugar. Timepoint: before & after intervention (3 months later). Method of measurement: glucose oxidase method.;Hb A1C. Timepoint: before & after intervention (3 months later). Method of measurement: colorimetry.;Insulin. Timepoint: before & after intervention (3 months later). Method of measurement: IRMA.;Insulin resistance. Timepoint: before & after intervention (3 months later). Method of measurement: insulin × glucose / 22.5.;Apo A. Timepoint: before & after intervention (3 months later). Method of measurement: immunotorbidometry.;Apo B. Timepoint: before & after intervention (3 months later). Method of measurement: immunotorbidometry.;Apo B/Apo A-I. Timepoint: before & after intervention (3 months later). Method of measurement: ratio.;High-sensitivity C-Reactive Protein. Timepoint: before & after intervention (3 months later). Method of measurement: ELISA kitt.;Total antioxidant capacity. Timepoint: before & after intervention (3 months later). Method of measurement: colorimetry (FRAP).;Malondealdehyde. Timepoint: before & after intervention (3 months later). Method of measurement: colorimetry.;Paraoxonase. Timepoint: before & after intervention (3 months later). Method of measurement: colorimetry.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Farzad Shidfar

School of Public Health of Tehran University of Medical Sciences

farzadshidfar@yahoo.com+98 21 8877 9118

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026